Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glomerulonephritis, Membranous Clear all
Recruiting Phase 3 Interventional

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Felzartamab, Tacrolimus, Standard of Care IST
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Huntsville, Alabama • Fresno, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT05732402
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Povetacicept
Drug
Lead sponsor
Alpine Immune Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 11:44 PM EDT
Recruiting No phase listed Observational

Nephrotic Syndrome Study Network

NCT01209000
View directory record Official record
Conditions
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions
Kidney Biopsy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Completed Not applicable Interventional

Vitamin D Supplementation in Glomerular Disease

NCT01835639
View directory record Official record
Conditions
Glomerular Disease
Interventions
Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Jul 23, 2026, 11:44 PM EDT
Completed Phase 1 Interventional

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

NCT00805753
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
ACTH
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Jul 23, 2026, 11:44 PM EDT
Recruiting No phase listed Observational

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

NCT05505500
View directory record Official record
Conditions
Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions
Interview
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 23, 2026, 11:44 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

NCT01762852
View directory record Official record
Conditions
Glomerulonephritis, Membranous
Interventions
Belimumab 10 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 23, 2026, 11:44 PM EDT
Completed Phase 4 Interventional Results available

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

NCT01386554
View directory record Official record
Conditions
Proteinuria, Idiopathic Membranous Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 23, 2026, 11:44 PM EDT
Recruiting Phase 2 Interventional

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT03949855
View directory record Official record
Conditions
Membranous Nephropathy, Nephrotic Syndrome
Interventions
Belimumab, Placebo for Belimumab, Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

NCT03453619
View directory record Official record
Conditions
IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
APL-2
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jul 23, 2026, 11:44 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

NCT05707377
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Zanubrutinib, Tacrolimus
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Granada Hills, California • Palo Alto, California • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Recruiting Phase 2Phase 3 Interventional

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Povetacicept, Tacrolimus
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Montgomery, Alabama • Surprise, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Withdrawn Phase 4 Interventional

ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

NCT01926054
View directory record Official record
Conditions
SLE Glomerulonephritis Syndrome, WHO Class V
Interventions
Acthar gel
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jul 23, 2026, 11:44 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

NCT03285711
View directory record Official record
Conditions
Lupus Membranous Nephropathy
Interventions
Filgotinib, Lanraplenib, Filgotinib placebo, Lanraplenib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Palo Alto, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Jul 23, 2026, 11:44 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

NCT01129284
View directory record Official record
Conditions
Treatment Resistant Nephrotic Syndrome
Interventions
ACTHAR gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Jul 23, 2026, 11:44 PM EDT
Recruiting Phase 3 Interventional

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT05696613
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
SNP-ACTH (1-39) Gel, Rituximab
Drug
Lead sponsor
Cerium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Los Angeles, California • San Dimas, California • Tarzana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Completed Phase 2Phase 3 Interventional Results available

MEmbranous Nephropathy Trial Of Rituximab

NCT01180036
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
Rituximab, Cyclosporine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jul 23, 2026, 11:44 PM EDT
Completed Phase 2 Interventional

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

NCT00050713
View directory record Official record
Conditions
Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Interventions
Sirolimus
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 23, 2026, 11:44 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

NCT07571746
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Surovatamig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Los Angeles, California • Iowa City, Iowa • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

NCT02682407
View directory record Official record
Conditions
IgAN, LN, MN, C3G
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Terminated Phase 1Phase 2 Interventional

Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

NCT04652570
View directory record Official record
Conditions
Membranous Nephropathy
Interventions
VB119
Drug
Lead sponsor
Tenet Medicines
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Albany, New York • Bethlehem, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Recruiting Phase 2 Interventional

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
ALXN1920, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Loma Linda, California • San Diego, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 11:44 PM EDT
Terminated Phase 1 Interventional

Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

NCT00479622
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
TRU-015
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Jul 23, 2026, 11:44 PM EDT